Overview

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects

Status:
NOT_YET_RECRUITING
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HS-10510 following single and multiple dose administration to healthy subjects with or without elevated Low-Density Lipoprotein-Cholesterol (LDL-C) levels. This study will consist of three parts (Parts AB and C). 32 subjects have been planned for Part A and up to 36 subjects for Part B and 20 subjects for Part C.
Phase:
PHASE1
Details
Lead Sponsor:
Jiangsu Hansoh Pharmaceutical Co., Ltd.